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INTRODUCTION
Cervical pregnancy is a serious complication of pregnancy
with a rare incidence of one per 2,400 (1) to 18,000 pregnan-
cies (2). The diagnosis is based upon a high degree of suspi-
cion and confirmed with either vaginal or abdominal sonog-
raphy (3, 4). In the past, hysterectomy was often the only
choice available because of profuse hemorrhage that accom-
panied the attempts of removal of the cervical pregnancy.
With the development of high resolution ultrasound and
sensitive serum  -human chorionic gonadotrophin ( -hCG)
assay, cervical pregnancy is diagnosed much earlier. There-
fore, various conservative surgical techniques are performed
in an effort to avoid hysterectomy and preserve fertility. The
surgical techniques include intra-cervical balloon tamponade
after cervical curettage (5), cervical cerclage (6, 7), angio-em-
bolization of feeding uterine arteries (8, 9), curettage and local
prostaglandin injection (10), hysteroscopic resection (11, 12)
and bilateral ligation of uterine or hypogastric arteries (13,
14). Nevertheless, such surgical methods still carry the risk
of uncontrollable bleeding and non-surgical methods using
methotrexate (MTX) (15-17), actinomycin-D (18) and etopo-
side (19) have recently been developed. Surgical techniques
are generally applied only when chemotherapy fails or in emer-
gency conditions of life-threatening acute hemorrhage (20).
In this study, we describe the clinical course of a series of
patients treated for cervical pregnancy with or without MTX.
The effects of MTX treatment is also evaluated.
MATERIALS AND METHODS
During the 85-month period from January 1993 through
February 2000, a total of 52,555 deliveries were performed at
the Department of Obstetrics & Gynecology, Samsung Cheil
Hospital & Women’s Healthcare Center, Sungkyunkwan Uni-
versity, School of Medicine, Seoul, Korea. Thirty-one cervical
pregnancies were detected during the same period. A retro-
spective study was conducted to describe the clinical course
of a series of patients treated for cervical pregnancy with or
without MTX. Of these 31 cases, 22 patients were treated
with MTX chemotherapy and the remaining nine patients
were treated with surgical procedures without MTX treat-
ment. Clinical characteristics, surgical procedures, MTX regi-
mens used, concomitant procedures, treatment results and
complications were retrospectively reviewed with medical
records.
Cervical pregnancy was diagnosed by ultrasound (21). The
diagnostic criteria included are as follows; first, there is no
evidence of an intrauterine pregnancy. Second, the cervix is
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Clinical Outcomes of Patients treated for Cervical Pregnancy with or
without Methotrexate 
The objective of this study is to describe the clinical outcomes of patients treated
for cervical pregnancy with or without methotrexate (MTX) and to evaluate the
effects of MTX in the treatment of cervical pregnancy. Between January 1993 and
February 2000, 31 patients were diagnosed with cervical pregnancy. Twenty-two
patients were treated with MTX chemotherapy and nine patients were treated with
surgical procedures without MTX treatment. In the non-MTX treatment group, three
patients underwent total abdominal hysterectomy, five required adjuvant procedures
to control the bleeding during dilatation and curettage (D&C) and only one patient
was treated with a simple D&C. In the MTX treatment group, fourteen (63.6%)
patients were treated with only MTX and eight (36.4%) cases underwent concomi-
tant procedures (simple curettage, curettage and Foley catheter tamponade, cer-
vical cerclage, ligation of the descending branches of uterine arteries, or ligation of
hypogastric arteries). The uterus was preserved in all cases and three women
delivered healthy babies in their subsequent pregnancy. In conclusion, early diag-
nosis, appropriate MTX regimen in combination of necessary adjuvant conserva-
tive procedures could contribute to successful treatment with preservation of the
uterus and future reproductive ability.
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distended and the uterus is hourglass shaped. Third, there is
conceptal or placental tissue in the cervix. Fourth, internal os
of the cervix is closed. The gestational age was determined
by the size of gestational sac by ultrasound (22). 
The MTX regimens varied among the physicians. It was
given systemically in a high-dose regimen (a dosage of 100
mg/m2 plus a dosage of 200 mg/m2 in normal saline solution
500 mL, intravenous injection) with folinic acid rescue, given
in low-dose prolonged regimen (1.0 mg/kg for a single dose
given every other day for 4 doses, intramuscular injection)
(23) or given as a single 50 mg MTX regimen (24). Folinic
acid rescue (0.1 mg/kg) was used after systemic MTX admin-
istration. Repeat treatments were indicated when the decrease
in serum  -hCG was below 15%, if vaginal bleeding per-
sisted or if gestational mass enlarged. 
Patients were monitored with ultrasound and serum  -
hCG level once a week until resolution of  -hCG level. After
serum  -hCG level normalization, the patients were followed
up with ultrasound once a month until the cervical mass re-
solved.
Student’s t-test and Fisher’s exact test were used for statis-
tical analysis. A p value of <.05 was considered statistically
significant.
RESULTS
The incidence of the cervical pregnancy was one in 1,695
live births. Patient characteristics of the MTX and non-MTX
treatment groups are compared in Table 1. The mean age of
the MTX treatment group was 31.3±3.6 yr, and 34.9±3.3
yr in the non-MTX treatment group. The mean gravidity and
parity were not statistically significant. The mean gestational
age was 6.3±1.1 and 7.9±2.7 weeks in the MTX and the
non-MTX treatment groups respectively. There were signif-
icant differences in patient age and gestational age. Past his-
tories of the patients were as follows; 25 had elective or spon-
taneous abortions, 13 had Cesarean deliveries, two had tubal
pregnancies, one had cone biopsy and resultant incompetent
internal os of the cervix and five developed cervical pregnancy
during in vitro fertilization (IVF) with embryo transfer (ET).
The clinical presentations and treatment outcomes in the
non-MTX treatment group are summarized in Table 2. The
mean gestational age was 7.9±2.7 weeks (range 6-13) and
regular heartbeat was detected in three cases (33%). Dilata-
tion and curettage (D&C) was performed in all nine cases.
However, three patients underwent total hysterectomy due to
uncontrollable uterine bleeding during D&C and five patients
required adjuvant procedures (gauze packing into the cervi-
cal canal, local vasopressin injection and compression with
ring forceps, recurettage, Foley catheter ballon tamponade,
or ligation of the descending branches of uterine arteries) to
control the bleeding from the cervical canal. Five patients
received blood transfusions.
The clinical presentations, MTX regimens used and treat-
ment outcomes in the MTX treatment group are summarized
in Table 3. The mean gestational age was 6.3±1.1 weeks
(range 5.3-9.6) and regular heartbeat was detected in 11 cases
(50%). Twelve patients received a systemic high dose MTX
regimen, four received a systemic low dose MTX regimen
and one received a single dose MTX regimen. Four patients
received a combination of a systemic high dose MTX regimen
with trans-cervical intra-amniotic injections of 2 mEq KCl
or 2 mL MTX and one received a single-dose MTX regimen
with trans-cervical intra-amniotic injection of 2 mEq KCl.
p value
non-MTX treatment
group (n=9)
MTX treatment 
group (n=22)
Mean age (yr) 31.3±3.6 34.9±3.3 .01
Gravity 3.0±1.6 3.1±1.4 NS
Parity 0.9±0.9 1.2±0.7 NS
Gestational age (wks) 6.3±1.1 7.9±2.7 .02
Past Ob & Gyn histories NS
Cesarean section 7 6
Abortion 18 7
Ectopic pregnancy 2 0
IIOC 1 0
ART 3 2
Table 1. The comparison of patient characteristics in the MTX
and non-MTX treatment groups
D/C, dilatation and curettage; MTX, methotrexate; HB, heart beat; GA, gestational age; TAH, total abdominal hysterectomy;  -hCG: -human  chori-
onic gonadotrophin; NA, not mentioned.
Case (No.) GA (wks) HB -hCG (mIU/mL) Transfusion (pints) Management
16 - NA 1 D/C, gauze packing
21 3 - NA 10 D/C, TAH due to uncontrollable bleeding
31 2 - NA 9 D/C, local injection with vasopressin, and compression with ring forcep
4 6.1 - NA 0 D/C, recurettage due to prolonged bleeding
56 - NA 2 D/C, TAH due to uncontrollable bleeding
67 - 1,570 2 D/C, TAH due to rupture of low uterine segment
7 7.3 + NA 0 D/C, ligation of the descending branches of uterine arteries
8 6.5 + NA 0 D/C, Foley catheter ballooning
9 6.6 + NA 0 D/C
Table 2. Clinical presentations, and results in the non-MTX treatment group
MTX, methotrexate; IIOC, incompetent internal os of cervix; ART, assisted
reproductive technique; Past Ob & Gyn histories, Past Obstetrics and
Gynecological histories. Data are presented as mean±SD or number.850 T.J. Kim, S.J. Seong, K.J. Lee, et al.
A single course of systemic MTX treatment failed to cease
the cardiac activity in all four cases beyond 7 weeks of ges-
tational age. The mean number of MTX treatment courses
was 2.5±1.8 (range 1-7). The mean initial  -hCG level was
44,183 mIU/mL (range 556-331,000). The mean time until
-hCG level resolution after treatment initiation was 60.3±
32.5 days (range 14-140). A gradual decline in  -hCG level
after MTX treatment initiation was noted in all cases but for
one in which  -hCG level rose progressively until 7 days
after the fetal demise. After MTX administration, 19 patients
underwent sonographic follow-up and 13 had a dispropor-
tionately enlarged cervical mass despite  -hCG level decli-
nation. The mean period from treatment initiation until sono-
graphic non-visualization of the cervical mass was 72.4±43.8
days (range 12-180). MTX-related side effects such as nau-
sea, vomiting, elevated serum liver enzyme activities and fever
developed in four patients (18%) after systemic injection. All
of the reported side effects were self-limited and subsided
within 14 days. Seven patients received blood transfusions.
During the follow-up period, fourteen patients (63.6%) did
not require any concomitant procedures whereas the other
eight (36.4%) underwent various concomitant procedures.
Concomitant surgical procedures (simple curettage, curettage
and Foley catheter tamponade, cervical cerclage, ligation of
the descending branches of uterine arteries, or ligation of the
hypogastric arteries) in conjunction with MTX therapy were
performed in cases of uncontrollable bleeding requiring trans-
fusion. In all cases, the uterus was preserved and menstrual
patterns returned to normal. After treatment, fifteen women
attempted subsequent pregnancies and three delivered nor-
mal and healthy babies.
HB, heartbeat; MTX, methotrexate.
MTX MTX+concomitant procedures Total p value
HB (+) 5 (45.5%) 6 (54.5%) 11 (100%) NS
HB (-) 9 (81.8%) 2 (18.2%) 11 (100%)
Table 4. Relationship between concomitant procedures and HB
in the MTX treatment group
GA, gestational age; MTX, methotrexate.
MTX Total p value
MTX+concomitant
procedures
GA≤6 weeks 8 (80.0%) 2 (20.0%) 10 (100%) NS
GA>6 weeks 6 (50.0%) 6 (50.0%) 12 (100%)
Table 5. Relationship between concomitant procedures and GA
in the MTX treatment group
GA, gestational age; HB, heartbeat;  -hCG,  -human chorionic gonadotrophin; MTX, methotrexate; NA, not mentioned; TAH, total abdominal hys-
terectomy; High, high dose systemic administration; Low, low dose systemic administration; Local, intra-amniotic or intra-cardiac injection; Single, sin-
gle dose systemic administration; ligation of hypogastric a., ligation of hypogastric artery; N/V, nausea and vomiting; ligation of the descending branch-
es of ut. a., ligation of the descending branches of the uterine artery.
Remission days
of -hCG
Concomitant 
procedures
Feticide
Side effect 
of MTX
No. of
MTX
MTX regimens -hCG
(mIU/mL)
Transfusion
(pints)
HB
GA
(wks)
No.
1 5.6 + 2 47,000 High 2 -- Laparotomy 67
2 5.6 + 0 NA Low 1 N/V --29
3 6.6 + 0 5,800 High 1 - + - 74
4 6 + 4 24,700 High 2 Fever, Liver enzyme � - D/C 47
5 6 + 0 18,600 High 5 -- D/C 80
6 6.6 + 0 6,100 High 1 -- - 80
7 6 + 2 16,200 High 2 Liver enzyme � - D/C, Foley catheter ballooning 60
8 7 + 0 54,000 Local, single 4 - + - 55
9 7 + 0 331,000 High, local, single 7 - + - 110
10 9.6 + 7 196,000 High, local 4 - + D/C, ligation of hypogastric a. 140
Foley catheter ballooning
11 8.3 + 4 94,000 High 2 - +D / C6 0
12 5.3 - 0 15,800 High 2 -- - 80
13 5.5 - 0 5,000 Low 4 Liver enzyme � --54
14 7 - 0 4,140 High 1 -- - 30
15 6 - 2 7,100 High 1 -- - 0
16 5.6 - 0 29,400 High 2 -- - 45
17 5 - 0 580 Low 1 -- - 14
18 5.5 - 0 19,000 High 1 -- - 70
19 7.5 - 0 556 Single 6 -- - 40
20 5.5 - 0 5,100 High 2 -- - 130
21 6.1 - 4 3,480 Low 1 -- D/C 19
22 5 - 0 3,380 High 2 -- D/C, cervical cerclage, 
ligation of the descending branches of ut. a.
Table 3. Clinical presentations, MTX regimens and results in the MTX treatment groupCervical Pregnancy and Methotrexate  851
Regular heartbeat and gestational age were considered im-
portant factors requiring concomitant procedures in the MTX
treatment group. However, these factors failed to show sta-
tistical significance after separate analysis (Table 4, 5). 
There were two cases of heterotopic cervical pregnancy after
IVF with ET. One case is a single cervical pregnancy and a
single intrauterine gestation (Table 3, Case 8) and another is
a single cervical pregnancy and triple intrauterine gestation
(Table 3, Case 9). Elective abortions were performed on all
fetuses in the cervix and uterus with transvaginal ultrasound-
guided intra-amniotic MTX injection. All gestational tis-
sue within the uterus and cervix was absorbed spontaneous-
ly without the need of curettage.
There were two interesting cases in the MTX-treatment
group. One patient (Table 3, Case 1) had profuse uterine bleed-
ing requiring transfusions 37 days after the first MTX chemo-
therapy. Laparotomy for uterine artery ligation was attempt-
ed but failed due to a large irremovable cervical mass reach-
ing the pelvic bone. Instead, a second course of systemic high
dose MTX was administered and uterine bleeding ceased 2
days afterwards. The cervical mass completely resolved 180
days after beginning of the first MTX treatment.
Another patient (Table 3, Case 10) of gestational age 9.6
weeks presented with a 2 cm dilated exocervix with bulging
amniotic sac. Local injection of MTX agent could not be
given in fear of membrane rupture and bleeding. Systemic
high dose MTX therapy was initiated but fetal cardiac activi-
ty failed to cease even 7 days after MTX injection. On day
10, MTX 50 mg was locally instilled into the amniotic cav-
ity under transabdominal sonographic guidance. However,
the fetal cardiac activity persisted. After the fourth MTX
administration, anhydramnios and upward fetal growth result-
ed in exocervix closure and intra-fetal injection of 2 mEq KCl
was possible. This method proved to be effective in halting
the fetal cardiac activity. After 2 months, the dead fetus spon-
taneously passed but the placenta was retained in the cervix.
Curettage was performed to remove the retained placenta but
bleeding of about 1,000 mL occurred within 20 min. The
bleeding was managed with bilateral hypogastric artery lig-
ation and Foley catheter balloon tamponade in the cervical
canal. Uterine bleeding continued at a rate of 20 mL/hr for
24 hr then gradually decreased and eventually stopped 2 days
after the surgery.
DISCUSSION
Cervical pregnancy is a rare form of ectopic gestation which
is often associated with a significant morbidity and a disas-
trous effect on future fertility. The true incidence of cervical
pregnancy cannot be precisely determined, but reviews of
literature indicate that the incidence may be on the rise from
one in 2,400 (2) to 18,000 pregnancies (1). In our study, the
incidence of the cervical pregnancy was one in 1,695 live
births. The incidence also appears to be increasing, in part,
due to recent developments in novel forms of assisted repro-
ductive techniques, especially IVF and ET (25). Improper
placement of the fertilized ovum and manipulation within
the cervical canal could increase the likelihood for cervical
implantation (26). Cervical pregnancy developed in 5 patients
during IVF and ET in our study. Thirteen of our patients had
a history of Cesarean delivery and twenty-five patients had
elective or spontaneous abortion.
The success rate of MTX treatment in cervical pregnancy
has been reported as high as 81.3% (27). MTX chemother-
apy combined with adjuvant conservative procedures has a
success rate of 94% and 91% in the viable and the non-viable
cervical pregnancy groups respectively. Fetal viability may
not affect treatment efficacy. The viable and non-viable group
each requires concomitant minor operative procedures dur-
ing the treatment course in 43% and 13%, such as endocer-
vical curettage, cervical balloon tamponade, and uterine artery
embolization (28, 29). An average of 53 days is required after
initiation of MTX therapy for the uterus to return to non-
pregnant status (28). In our study, the mean period from treat-
ment initiation till sonographic resolution of the cervical mass
was 72.4 days. The viability of the cervical pregnancy and
the size of gestational sac may not affect the efficacy of treat-
ment. However, the concomitant procedures were required
54% in the viable and 18.2% in the non-viable group, and
50% in the beyond 6 weeks of gestational age and 20% in
the less than 6 weeks of gestational age group, respectively.
Therefore, physicians must consider the need of concomitant
procedures in cases with fetal heart beat or beyond 6 weeks
of gestational age. With MTX chemotherapy and concomi-
tant use of surgical procedures in selected cases, the uterus
could be preserved in all cases (100%), this result concurs
with the study of Kung et al. (28).
The regression of the cervical hypervascular mass after MTX
treatment is related to the decline in the  -hCG level. Although
a disproportionately enlarged cervix will progressively shrink
as  -hCG level declines, enlargement may still be present
even after serum  -hCG level becomes undetectable (30). We
observed 13 cases of disproportionately enlarged cervical mass
despite  -hCG level decline. Nevertheless, no attempt should
be made to reduce the size of the asymptomatic hypervascu-
lar cervical mass as such manipulation of the cervix may cause
bleeding fraught with serious consequences.
MTX-related side effects such as gastrointestinal upset,
pharyngitis, stomatitis, elevated serum liver enzyme activi-
ties, leukopenia, thrombocytopenia, conjunctivitis, and fever
developed in 14 (29%) of 48 patients after the systemic injec-
tion (28). In our study, MTX-related side effects was noted
in 4 (18%) out of 22 patients.
Based on our study, systemic MTX administration com-
bined with intra-cardiac feticide with either MTX or KCl
appears to be effective treatment in cases of viable cervical
pregnancy beyond 7 weeks of gestational age. Systemic MTX852 T.J. Kim, S.J. Seong, K.J. Lee, et al.
administration alone was effective in almost all cases of non-
viable and viable cervical pregnancy at gestational age below
7 weeks. However, if the bleeding is not profuse after one or
two courses of MTX, the patient may be observed until the
cervical mass resolves. With profuse or prolonged bleeding,
blood transfusions may be required and concomitant proce-
dures for bleeding control should be considered.
In conclusion, early diagnosis, appropriate MTX regimen
and combination of necessary adjuvant conservative proce-
dures could contribute to successful treatment with preser-
vation of the uterus and future reproductive ability.
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